Search Results

Aspen Neuroscience, Inc. has received a CLIN2 grant award of $8 million from the California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, to support clinical research aimed at treating Parkinson’s disease (PD).

Lineage Cell Therapeutics, Inc. today announced that the Company has received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM).

Senti Biosciences, Inc., a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, announced that the California Institute for Regenerative Medicines has awarded an $8 million grant to Senti Bio.

Andelyn Biosciences, Inc. has been selected to manufacture adeno-associated vectors therapies using its suspension AAV Curator™ Platform under the California Institute for Regenerative Medicine Accelerating Medicines Partnership Bespoke Gene Therapy Consortium.

Funding will advance development of Rejuvenate’s one-time gene therapy RJB-0402 for the treatment of desmoplakin gene variant arrhythmogenic cardiomyopathy

Allogene Therapeutics, Inc. announced that it has received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of ALLO-316, an AlloCAR T™ investigational product targeting CD70 in development for the treatment of advanced or metastatic renal cell carcinoma (RCC).

Calidi Biotherapeutics Inc. and City of Hope jointly announced that the CIRM has awarded Karen Aboody, M.D., City of Hope professor in the Department of Stem Cell Biology and Regenerative Medicine and Division of Neurosurgery, a $5.3 million grant to fund preclinical translational studies, product manufacturing, and clinical trial design using Calidi’s licensed oncolytic virotherapy product, CLD-101, in patients with chemo-resistant, metastatic ovarian cancer.

Avid Bioservices, Inc. announced a new partnership with the California Institute for Regenerative Medicine Industry Resource Partner Program.

Siren Biotechnology announced that the California Institute for Regenerative Medicine has awarded the company a $4M translational research grant to support the development of novel AAV immuno-gene therapies for cancer.